Computational modelling of resistance and associated treatment response heterogeneity in metastatic cancers.

Computational modelling of resistance and associated treatment response heterogeneity in metastatic cancers. Phys Med Biol. 2019 Feb 21;: Authors: Turk M, Simoncic U, Roth A, Valentinuzzi D, Jeraj R Abstract Metastatic cancer patients invariably develop treatment resistance. Different levels of resistance lead to observed heterogeneity in treatment response. The main goal was to evaluate treatment response heterogeneity with computation model simulating dynamics of drug-sensitive and drug-resistant cells. Model parameters included proliferation, drug induced death, transition and proportion of intrinsically resistant cells. Model was benchmarked with imaging metric extracted from 39 metastatic prostate cancer patients who had 18F-NaF-PET/CT scans performed at baseline and three cycles into chemotherapy or hormonal therapy. Two initial model assumptions were evaluated: considering only inter-patient or both inter-patient and intra-patient heterogeneity in proportion of intrinsically resistant cells. Correlation between median proportion of intrinsically resistant cells and baseline patient-level imaging metrics was assessed with Spearman's rank correlation coefficient. Impact of model parameters on simulated treatment response was evaluated with sensitivity study. Treatment response after six, nine and twelve months was predicted with the model. Median predicted range of response for patients treated with both therapies was compared with wilcoxon rank sum...
Source: Physics in Medicine and Biology - Category: Physics Authors: Tags: Phys Med Biol Source Type: research

Related Links:

PMID: 31540596 [PubMed - in process]
Source: Health Physics - Category: Physics Authors: Tags: Int J Radiat Oncol Biol Phys Source Type: research
Publication date: Available online 21 September 2019Source: Pathology - Research and PracticeAuthor(s): Rahul Mannan, Alexander S. Taylor, Daniel E. Spratt, Arul M. Chinnaiyan, Jeffrey S. Montgomery, Noah A. Brown, Rohit MehraAbstractBladder cancer continues to be a source of disease burden worldwide. In patients with a long-standing history of prostate cancer, distinguishing between new/independent and synchronous poorly differentiated urothelial carcinoma (UCA) and residual/recurrent high grade/poorly differentiated prostatic adenocarcinoma or prostatic adenocarcinoma with therapy-related changes can be diagnostically an...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
CONCLUSIONS: These results suggest that FENDRR in prostate cancer may reduce tumor invasion in prostate cancer PC-3 cells by targeting CSNK1E, which may have favourable effort to better understand the underlying pathogenesis of prostate cancer and provide a tough theoretical basis for further studying prostate cancer. PMID: 31539119 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
PROSTATE cancer often does not have any obvious symptoms initially, but as the cancer grows they may begin to start showing. You could be at risk however, if you have this sexual symptom. What is it?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Publication date: Available online 20 September 2019Source: Biosensors and BioelectronicsAuthor(s): Zhen Rong, Zikun Bai, Jianing Li, Hao Tang, Tianyi Shen, Qiong Wang, Chongwen Wang, Rui Xiao, Shengqi WangAbstractSimultaneous detection of free and complexed prostate-specific antigen (f-PSA and c-PSA) is critical to the prostate cancer (PCa) diagnostic accuracy for clinical samples with PSA values in the diagnostic gray zone between 4 and 10 ng mL−1. Herein, red and green magnetic-quantum dot nanobeads (MQBs) with superior magnetic property and high luminescence were fabricated via polyethyleneimine-intermediated...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research
Publication date: September 2019Source: European Urology Supplements, Volume 18, Issue 6Author(s): A. Aydin, C. Kahir, M. Patel, C. Allen, P. Dasgupta
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Publication date: September 2019Source: European Urology Supplements, Volume 18, Issue 6Author(s): E. Koseoglu, A.E. Canda, B. Cil, M.C. Kiremit, K. Tarim, H. Nuhoglu, Y. Kordan, M.D. Balbay, T. Esen
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Publication date: September 2019Source: European Urology Supplements, Volume 18, Issue 6Author(s): Y. Raskin, M. Joris, G. Devos, V. Caldéron Plazarte, W. Everaerts, S. Joniau
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Publication date: September 2019Source: European Urology Supplements, Volume 18, Issue 6Author(s): M. Covas Moschovas, B. Seetharam, F.F Onol, T. Rogers, V. Patel
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
ConclusionsNot only mp-MRI and MRI-targeted sampling, but also concomitant systematic biopsies provide significant information to identify patients at a higher risk of adverse pathology. Although omitting systematic prostate sampling at the time of MRI-targeted biopsy might be associated with a reduced risk of detecting insignificant PCa and lower patient discomfort, it reduces the ability to accurately predict pathological features.Patient summaryThe combination of multiparametric magnetic resonance imaging (mp-MRI) with accurate biopsy information on MRI-targeted and systematic biopsies improves the accuracy of multivari...
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Chemotherapy | CT Scan | Hormonal Therapy | Hormones | PET Scan | Physics | Prostate Cancer | Study